Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
aTyr Pharma announced FDA alignment on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis and plans to start study activities in Q4 2026.Key Highlights:Original SEC Filing: aTYR PHARMA INC [ ATYR ] - 8-K - Sep. 24, 2026This is an AI-powered summary. It may contain inaccuracies. Cons…
aTyr Pharma aligned with FDA on a global Phase 3 protocol for efzofitimod in pulmonary sarcoidosis using FVC at week 48 as the primary endpoint; study activities are expected to begin in Q4 2026 and will require additional capital.Material DetailsContext by AI AnalystThis is a mid-cycle development…
aTyr Pharma aligned with the FDA on a Phase 3 efzofitimod trial in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study-related activities are expected to start in Q4 2026 as the company prepares U.S. and European regulatory submissions. Trial will test whether efzofitimod can improve lung fu